You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
The Authors' reply
  1. Andres Cardenas1,2,
  2. Pere Gines2,3
  1. 1GI Unit, Institut Clinic de Malalties Digestives i Metaboliques, Hospital Clinic, Barcelona, Spain
  2. 2Institut d'Investigacions Biomèdiques August Pi-Sunyer (IDIBAPS), University of Barcelona, Ciber de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain
  3. 3Liver Unit, Institut Clinic de Malalties Digestives i Metaboliques, Hospital Clinic, Barcelona, Spain
  1. Correspondence to Dr Pere Gines, Liver Unit, Institut Clinic de Malalties Digestives, Hospital clinic I provincial, Barcelona, Catalunya, Spain; pgines{at}clinic.ub.es

https://doi.org/10.1136/gutjnl-2011-300084

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Dr Hutchinson and Dr Davies for their comments1 regarding the use of alternative options in patients with cirrhosis and refractory ascites. The use of other potential therapies for patients with refractory ascites is attractive and should perhaps be considered in selected cases. Therapies such as clonidine, a centrally acting α2-agonist and sympatholytic agent, and the use of vasoconstrictors such as midodrine have been …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.